Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ADA 2021: Encouraging Trial Data On CGMs, Insulin Pens, Digital Solutions, And More

Executive Summary

The American Diabetes Association held its 81st Scientific Sessions from 25-29 June, where a range of presentations covering clinical trials of continuous glucose monitors, insulin-delivery systems and remote monitoring technologies were given.

You may also be interested in...



Exec Chat: Dexcom’s CEO Bullish On Year Ahead With G7 CGM Launch, Dexcom One CGM Expansion

In an interview with Medtech Insight following the J.P. Morgan Health Care Conference, Dexcom CEO Kevin Sayer discussed marketing plans for the next-generation G7 continuous glucose monitoring system and for the simpler CGM, Dexcom One, and outlined plans ahead.

LifeScan Announces Partnership With Fitbit To Monitor Blood Glucose

The collaboration will provide a Fitbit smartwatch to users of LifeScan’s OneTouch Reveal blood glucose monitoring app.

Exec Chat: Dexcom Continues To Evolve Blood Glucose Measurement Market

In an interview with Medtech Insight, Dexcom CEO Kevin Sayer discussed his views on the blood glucose measurement market, how he thinks it will change, and Dexcom’s responsibilities to patients, regulators and payors.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT144145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel